MEK1/2 inhibitor ABM-168

{
  "id": "MLC-T-ONC-015069",
  "term": "MEK1/2 inhibitor ABM-168",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, brain-penetrant, allosteric inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, MEK1/2 inhibitor ABM-168 selectively binds to and inhibits the activity of MEK1 and MEK2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations. ABM-168 is able to cross the blood-brain barrier (BBB).",
  "synonyms": [
    "MEK 1/2 inhibitor ABM-168"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mek1-2-inhibitor-abm-168/"
}